Skip to main content

Table 4 Baseline descriptive statistics of the treatment subgroups with liver T2* value < 9.2 ms

From: Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

  P Deferiprone group (n = 23) Combined group (n = 41) Deferoxamine group (n =33) P
Age (yrs) 0.376 30.6 ± 6.1 28.9 ± 6.2 30.3 ± 8.3 0.439
Male (%) 0.108 69.6% 48.8% 51.5% 0.815
Chel. starting age (yrs) 0.548 5.1 ± 5.7 4.2 ± 4.3 5.4 ± 3.9 0.326
Ferritin (ng/l) <0.0001 1347 ± 1782 2101 ± 944 1729 ± 1672 0.009
Liver T2* (ms) 0.733 3.3 ± 2.1 3.6 ± 2.3 4.0 ± 2.0 0.272
MRI LIC (mg/g dry weight) 0.940 12.5 ± 9.5 12.3 ± 10.2 9.6 ± 7.2 0.197
  1. All values are quoted as mean ± SD.